Viralytics Ltd. - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 32
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: V3FE718E598EN
Leaflet:

Download PDF Leaflet

Viralytics Ltd. - Product Pipeline Review - Q4 2010
Viralytics Ltd. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Viralytics Ltd. – Product Pipeline Review – Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Viralytics Ltd. – Brief company overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Viralytics Ltd. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Viralytics Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Viralytics Ltd.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Viralytics Ltd.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Viralytics Ltd. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Viralytics Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Viralytics Ltd..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Viralytics Ltd. and identify potential opportunities in those areas.
Viralytics Ltd. Snapshot
Viralytics Ltd. Overview
Key Information
Key Facts
Viralytics Ltd. – Research and Development Overview
Key Therapeutic Areas
Viralytics Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Viralytics Ltd. – Pipeline Products Glance
Viralytics Ltd. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Viralytics Ltd.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Viralytics Ltd. – Drug Profiles
Cavatak
  Product Description
  Mechanism of Action
  R&D Progress
Cavatak
  Product Description
  Mechanism of Action
  R&D Progress
Echovirus-1
  Product Description
  Mechanism of Action
  R&D Progress
CVA21 DAF
  Product Description
  Mechanism of Action
  R&D Progress
Viralytics Ltd. – Pipeline Analysis
Viralytics Ltd. – Pipeline Products by Therapeutic Class
Viralytics Ltd. Pipeline Products By Target
Viralytics Ltd. – Pipeline Products by Route of Administration
Viralytics Ltd. – Pipeline Products by Molecule Type
Viralytics Ltd. – Locations And Subsidiaries
Head Office
Recent Developments
Jan 19, 2010: Viralytics Completes Phase I Cavatak Trial
Dec 18, 2009: Viralytics Receives Approval To Increase CAVATAK Dosage In Head And Neck Cancer Trial
Dec 09, 2008: Viralytics To Test CAVATAK In Head And Neck Cancer
Dec 09, 2008: Positive Pre-Clinical Research Results On CAVATAK In Human Brain Cancer
Mar 30, 2007: Publication Of Data concerning CAVATAK In Multiple Myeloma
Dec 21, 2005: The FDA Grants Orphan Drug Designation To Psiron Ltd For Cavatak
Financial Deals Landscape
Viralytics Ltd., Deals Summary, 2004 to 2010
Viralytics Ltd. Detailed Deal Summary
Debt Offering
Viralytics Completes Private Placement Of Convertible Note For $6 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Viralytics Ltd. – Pipeline by Therapy Area and Indication, 2010
Viralytics Ltd. – Pipeline by Stage of Development, 2010
Viralytics Ltd. – Monotherapy Products in Pipeline, 2010
Viralytics Ltd. - Phase I, 2010
Viralytics Ltd. - Pipeline By Therapeutic Class, 2010
Viralytics Ltd. - Pipeline By Target, 2010
Viralytics Ltd. – Pipeline By Route of Administration, 2010
Viralytics Ltd. – Pipeline By Molecule Type, 2010
Viralytics Ltd., Deals Summary, 2004 to 2010 28

LIST OF FIGURES

Viralytics Ltd. – Pipeline by Therapy Area and Indication, 2010
Viralytics Ltd. – Pipeline by Stage of Development, 2010
Viralytics Ltd. – Monotherapy Products in Pipeline, 2010
Viralytics Ltd. – Pipeline By Therapeutic Class, 2010
Viralytics Ltd. - Pipeline By Target, 2010
Viralytics Ltd. – Pipeline By Route of Administration, 2010 21

Ask Your Question

Viralytics Ltd. - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: